| Tchem | CREB-binding protein |
This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]
Comments
Property Summary
| NCBI Gene PubMed Count | 469 |
| Grant Count | 397 |
| R01 Count | 255 |
| Funding | $28,706,372.43 |
| PubMed Score | 442.37 |
| PubTator Score | 1227.16 |
| Disease | log2 FC | p |
|---|---|---|
| Multiple myeloma | 1.067 | 0.011 |
| osteosarcoma | -1.529 | 0.000 |
| astrocytoma | 1.700 | 0.002 |
| subependymal giant cell astrocytoma | -1.753 | 0.004 |
| ovarian cancer | -1.200 | 0.000 |
CHEMBL3770322
pIC50 6.00
CHEMBL3770598
pIC50 6.00
CHEMBL3650917
pIC50 6.02
CHEMBL3650889
pIC50 6.02
CHEMBL3650929
pIC50 6.04
CHEMBL3813713
pIC50 6.05
CHEMBL3771341
pKd 6.10
CHEMBL3110353
pIC50 6.10
CHEMBL3770150
pKd 6.11
CHEMBL2335154
pIC50 6.11
CHEMBL3650891
pIC50 6.13
CHEMBL3581661
pKd 6.17
CHEMBL3814881
pIC50 6.17
CHEMBL3650894
pIC50 6.18
CHEMBL3650940
pIC50 6.19
CHEMBL3654293
pIC50 6.20
CHEMBL3108800
pIC50 6.20
CHEMBL3108803
pIC50 6.20
CHEMBL3813915
pIC50 6.21
CHEMBL3650905
pIC50 6.22
| PMID | Text |
|---|---|
| 26870802 | Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling |
| 26851278 | Intrinsic protein disorder plays a prominent role in the function and interactions of the transcriptional co-activators CBP and p300. (Review) |
| 26742101 | Computational simulations were used to understand how phosphorylation affects the structure of the p53 terminal transactivation domain in complex with the CBP TAZ2 domain. |
| 26628108 | high expression of both CREB-binding protein and cleavage and polyadenylation specific factor 4 predicted a poor prognosis in the patients with lung adenocarcinomas. |
| 26603346 | Case Report: novel nonsense mutation of CREBBP in a patient with Rubinstein-Taybi syndrome. |
| 26491150 | Kaposi's sarcoma-associated herpesvirus vIRF4 targets the beta-catenin/CBP cofactor and blocks its occupancy on the cyclin D1 promoter, suppressing the G1-S cell cycle progression and enhancing virus replication. |
| 26318425 | RFPL3 and CBP have roles in upregulating hTERT activity and promoting lung cancer growth |
| 26315281 | Disruption of beta-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair. |
| 26164627 | these findings suggest that sumoylation plays a critical role in the spatiotemporal co-activation of CLOCK-BMAL1 by CBP for immediate-early Per induction and the resetting of the circadian clock. |
| 26021349 | WNT/beta-catenin signaling does not affect nuclear translocation of the RelA subunit of NF-kappaB or its association with CBP (also known as CREBBP) |
| More... |
MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLVPDAASKHKQL 1 - 70 SELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSPLSQGDSSAPSLPKQAAST 71 - 140 SGPTPAASQALNPQAQKQVGLATSSPATSQTGPGICMNANFNQTHPGLLNSNSGHSLINQASQGQAQVMN 141 - 210 GSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPF 211 - 280 SQAGGQPMGATGVNPQLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEK 281 - 350 RKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWK 351 - 420 NCTRHDCPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALGL 421 - 490 PYMNQPQTQLQPQVPGQQPAQPQTHQQMRTLNPLGNNPMNIPAGGITTDQQPPNLISESALPTSLGATNP 491 - 560 LMNDGSNSGNIGTLSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLV 561 - 630 AYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQP 631 - 700 VRPPNGPLSLPVNRMQVSQGMNSFNPMSLGNVQLPQAPMGPRAASPMNHSVQMNSMGSVPGMAISPSRMP 701 - 770 QPPNMMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQA 771 - 840 SQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTPPGMTPPQPAAPTQPSTPVSSSGQTPTPTPGSVPSAT 841 - 910 QTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVAS 911 - 980 AETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPMEVDE 981 - 1050 KKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLL 1051 - 1120 GIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEID 1121 - 1190 PVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQT 1191 - 1260 TISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQ 1261 - 1330 TTRLGNHLEDRVNKFLRRQNHPEAGEVFVRVVASSDKTVEVKPGMKSRFVDSGEMSESFPYRTKALFAFE 1331 - 1400 EIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDSIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGH 1401 - 1470 IWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYF 1471 - 1540 EGDFWPNVLEESIKELEQEEEERKKEESTAASETTEGSQGDSKNAKKKNNKKTNKNKSSISRANKKKPSM 1541 - 1610 PNVSNDLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDAFLTLARDKHWEFSS 1611 - 1680 LRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLD 1681 - 1750 DEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCK 1751 - 1820 QLIALCCYHAKHCQENKCPVPFCLNIKHKLRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPP 1821 - 1890 GTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAAR 1891 - 1960 QIEREAQQQQHLYRVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQ 1961 - 2030 PMPGLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAF 2031 - 2100 IKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQA 2101 - 2170 LNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGPGGY 2171 - 2240 PPAMQQQQRMQQHLPLQGSSMGQMAAQMGQLGQMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQ 2241 - 2310 PNPMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSPQT 2311 - 2380 GSPHPGLAVTMASSIDQGHLGNPEQSAMLPQLNTPSRSALSSELSLVGDTTGDTLEKFVEGL 2381 - 2442 //
| PMID | Year | Title |
|---|---|---|
| 26870802 | 2015 | Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling. |
| 26851278 | 2016 | Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300. |
| 26742101 | 2016 | Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case. |
| 26628108 | 2016 | CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway. |
| 26603346 | 2016 | Identification of a novel de novo mutation of CREBBP in a patient with Rubinstein-Taybi syndrome by targeted next-generation sequencing: a case report. |
| 26491150 | 2015 | Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 4 (vIRF4) Perturbs the G1-S Cell Cycle Progression via Deregulation of the cyclin D1 Gene. |
| 26318425 | 2015 | RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth. |
| 26315281 | 2015 | Disruption of ?-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair. |
| 26164627 | 2015 | Sumoylation controls CLOCK-BMAL1-mediated clock resetting via CBP recruitment in nuclear transcriptional foci. |
| 26021349 | 2015 | WNT/?-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-?B target genes. |
| More... |
